CA2790380A1 - Vaccines for use in the prophylaxis and treatment of influenza virus disease - Google Patents
Vaccines for use in the prophylaxis and treatment of influenza virus disease Download PDFInfo
- Publication number
- CA2790380A1 CA2790380A1 CA2790380A CA2790380A CA2790380A1 CA 2790380 A1 CA2790380 A1 CA 2790380A1 CA 2790380 A CA2790380 A CA 2790380A CA 2790380 A CA2790380 A CA 2790380A CA 2790380 A1 CA2790380 A1 CA 2790380A1
- Authority
- CA
- Canada
- Prior art keywords
- amino acid
- polypeptide
- seq
- hydrophilic
- isolated
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 241000712461 unidentified influenza virus Species 0.000 title claims abstract 10
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title claims 5
- 201000010099 disease Diseases 0.000 title claims 4
- 229960005486 vaccine Drugs 0.000 title abstract 2
- 238000011321 prophylaxis Methods 0.000 title 1
- 238000011282 treatment Methods 0.000 title 1
- 108090000765 processed proteins & peptides Proteins 0.000 claims abstract 119
- 229920001184 polypeptide Polymers 0.000 claims abstract 118
- 102000004196 processed proteins & peptides Human genes 0.000 claims abstract 118
- 206010022000 influenza Diseases 0.000 claims abstract 43
- 239000000203 mixture Substances 0.000 claims abstract 21
- 101710154606 Hemagglutinin Proteins 0.000 claims abstract 4
- 101710093908 Outer capsid protein VP4 Proteins 0.000 claims abstract 4
- 101710135467 Outer capsid protein sigma-1 Proteins 0.000 claims abstract 4
- 101710176177 Protein A56 Proteins 0.000 claims abstract 4
- 239000000185 hemagglutinin Substances 0.000 claims abstract 4
- 150000001413 amino acids Chemical class 0.000 claims 92
- 230000002209 hydrophobic effect Effects 0.000 claims 34
- 241000700605 Viruses Species 0.000 claims 14
- 125000003275 alpha amino acid group Chemical group 0.000 claims 14
- 230000002163 immunogen Effects 0.000 claims 13
- 230000002378 acidificating effect Effects 0.000 claims 8
- 102000004169 proteins and genes Human genes 0.000 claims 7
- 108090000623 proteins and genes Proteins 0.000 claims 7
- 102000007999 Nuclear Proteins Human genes 0.000 claims 6
- 108010089610 Nuclear Proteins Proteins 0.000 claims 6
- 210000001744 T-lymphocyte Anatomy 0.000 claims 6
- 239000003937 drug carrier Substances 0.000 claims 6
- 239000012634 fragment Substances 0.000 claims 5
- 102000002689 Toll-like receptor Human genes 0.000 claims 4
- 108020000411 Toll-like receptor Proteins 0.000 claims 4
- 229910052739 hydrogen Inorganic materials 0.000 claims 4
- 239000003446 ligand Substances 0.000 claims 4
- 102000014914 Carrier Proteins Human genes 0.000 claims 3
- 108010078791 Carrier Proteins Proteins 0.000 claims 3
- 108010040721 Flagellin Proteins 0.000 claims 3
- 241000607142 Salmonella Species 0.000 claims 3
- 208000037797 influenza A Diseases 0.000 claims 3
- 102000039446 nucleic acids Human genes 0.000 claims 3
- 108020004707 nucleic acids Proteins 0.000 claims 3
- 150000007523 nucleic acids Chemical class 0.000 claims 3
- 241000711404 Avian avulavirus 1 Species 0.000 claims 2
- 239000002671 adjuvant Substances 0.000 claims 2
- 230000003053 immunization Effects 0.000 claims 2
- 108010045069 keyhole-limpet hemocyanin Proteins 0.000 claims 2
- 239000011159 matrix material Substances 0.000 claims 2
- 239000002245 particle Substances 0.000 claims 2
- 230000009385 viral infection Effects 0.000 claims 2
- GOJUJUVQIVIZAV-UHFFFAOYSA-N 2-amino-4,6-dichloropyrimidine-5-carbaldehyde Chemical group NC1=NC(Cl)=C(C=O)C(Cl)=N1 GOJUJUVQIVIZAV-UHFFFAOYSA-N 0.000 claims 1
- 241000702421 Dependoparvovirus Species 0.000 claims 1
- 241000712431 Influenza A virus Species 0.000 claims 1
- 241000713196 Influenza B virus Species 0.000 claims 1
- 239000002202 Polyethylene glycol Substances 0.000 claims 1
- 241000700618 Vaccinia virus Species 0.000 claims 1
- 210000004027 cell Anatomy 0.000 claims 1
- 125000003630 glycyl group Chemical group [H]N([H])C([H])([H])C(*)=O 0.000 claims 1
- 230000003472 neutralizing effect Effects 0.000 claims 1
- 229920001223 polyethylene glycol Polymers 0.000 claims 1
- 241000701161 unidentified adenovirus Species 0.000 claims 1
- 241001430294 unidentified retrovirus Species 0.000 claims 1
- 230000028993 immune response Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
- C07K14/08—RNA viruses
- C07K14/11—Orthomyxoviridae, e.g. influenza virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/53—DNA (RNA) vaccination
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
- A61K2039/6012—Haptens, e.g. di- or trinitrophenyl (DNP, TNP)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
- A61K2039/6031—Proteins
- A61K2039/6081—Albumin; Keyhole limpet haemocyanin [KLH]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/16011—Orthomyxoviridae
- C12N2760/16111—Influenzavirus A, i.e. influenza A virus
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/16011—Orthomyxoviridae
- C12N2760/16111—Influenzavirus A, i.e. influenza A virus
- C12N2760/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/16011—Orthomyxoviridae
- C12N2760/16111—Influenzavirus A, i.e. influenza A virus
- C12N2760/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Virology (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Communicable Diseases (AREA)
- Pulmonology (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Oncology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (9)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US30589810P | 2010-02-18 | 2010-02-18 | |
| US61/305,898 | 2010-02-18 | ||
| US12/788,103 | 2010-05-26 | ||
| US12/788,103 US8673314B2 (en) | 2009-05-26 | 2010-05-26 | Monoclonal antibodies against influenza virus generated by cyclical administration and uses thereof |
| US35416010P | 2010-06-11 | 2010-06-11 | |
| US61/354,160 | 2010-06-11 | ||
| US38508310P | 2010-09-21 | 2010-09-21 | |
| US61/385,083 | 2010-09-21 | ||
| PCT/US2011/025467 WO2011103453A2 (en) | 2010-02-18 | 2011-02-18 | Vaccines for use in the prophylaxis and treatment of influenza virus disease |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA2790380A1 true CA2790380A1 (en) | 2011-08-25 |
Family
ID=44483593
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA2790380A Abandoned CA2790380A1 (en) | 2010-02-18 | 2011-02-18 | Vaccines for use in the prophylaxis and treatment of influenza virus disease |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US9701723B2 (enExample) |
| EP (1) | EP2536425B1 (enExample) |
| JP (3) | JP2013520172A (enExample) |
| KR (1) | KR20120132506A (enExample) |
| CN (1) | CN102939096B (enExample) |
| AU (1) | AU2011217903B2 (enExample) |
| BR (1) | BR112012020839A2 (enExample) |
| CA (1) | CA2790380A1 (enExample) |
| MX (1) | MX342716B (enExample) |
| WO (1) | WO2011103453A2 (enExample) |
Families Citing this family (34)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2010117786A1 (en) | 2009-03-30 | 2010-10-14 | Mount Sinai School Of Medicine Of New York University | Influenza virus vaccines and uses thereof |
| JP5941841B2 (ja) | 2009-05-26 | 2016-06-29 | アイカーン スクール オブ メディシン アット マウント サイナイ | 周期的投与によって作製されたインフルエンザウイルスに対するモノクローナル抗体及びその使用 |
| AU2011217903B2 (en) | 2010-02-18 | 2017-03-02 | Mount Sinai School Of Medicine | Vaccines for use in the prophylaxis and treatment of influenza virus disease |
| US9708373B2 (en) | 2010-03-30 | 2017-07-18 | Icahn School Of Medicine At Mount Sinai | Influenza virus vaccine and uses thereof |
| WO2013043729A1 (en) | 2011-09-20 | 2013-03-28 | Mount Sinai School Of Medicine | Influenza virus vaccines and uses thereof |
| EP2934581B1 (en) | 2012-12-18 | 2022-09-14 | Icahn School of Medicine at Mount Sinai | Influenza virus vaccines and uses thereof |
| WO2014159960A1 (en) | 2013-03-14 | 2014-10-02 | Icahn School Of Medicine At Mount Sinai | Antibodies against influenza virus hemagglutinin and uses thereof |
| US9616114B1 (en) | 2014-09-18 | 2017-04-11 | David Gordon Bermudes | Modified bacteria having improved pharmacokinetics and tumor colonization enhancing antitumor activity |
| WO2016118937A1 (en) | 2015-01-23 | 2016-07-28 | Icahn School Of Medicine At Mount Sinai | Influenza virus vaccination regimens |
| US10676723B2 (en) | 2015-05-11 | 2020-06-09 | David Gordon Bermudes | Chimeric protein toxins for expression by therapeutic bacteria |
| KR101768600B1 (ko) * | 2015-05-18 | 2017-08-17 | 한국생명공학연구원 | 범용성 개 인플루엔자 바이러스 백신 조성물 |
| JP6868763B2 (ja) * | 2016-04-01 | 2021-05-12 | パナソニックＩｐマネジメント株式会社 | インフルエンザウィルスに結合する抗体 |
| US11266734B2 (en) | 2016-06-15 | 2022-03-08 | Icahn School Of Medicine At Mount Sinai | Influenza virus hemagglutinin proteins and uses thereof |
| US10478488B2 (en) | 2017-10-03 | 2019-11-19 | Southwest Research Institute | Liposomal flu vaccine formulation |
| US11129906B1 (en) | 2016-12-07 | 2021-09-28 | David Gordon Bermudes | Chimeric protein toxins for expression by therapeutic bacteria |
| US11180535B1 (en) | 2016-12-07 | 2021-11-23 | David Gordon Bermudes | Saccharide binding, tumor penetration, and cytotoxic antitumor chimeric peptides from therapeutic bacteria |
| EP3606555A4 (en) | 2017-04-07 | 2021-08-04 | Icahn School of Medicine at Mount Sinai | INFLUENZA B VIRUS NEURAMINIDASE ANTIBODIES AND USES THEREOF |
| AU2018357917B2 (en) | 2017-10-30 | 2024-08-01 | Takeda Pharmaceutical Company Limited | Environmentally compatible detergents for inactivation of lipid-enveloped viruses |
| RU2757013C2 (ru) * | 2017-12-19 | 2021-10-08 | Федеральное государственное бюджетное учреждение "Научно-исследовательский институт гриппа имени А.А. Смородинцева" Министерства здравоохранения Российской Федерации | Рекомбинантная противогриппозная вакцина с широким спектром защиты и способ ее получения |
| CN108287235B (zh) * | 2018-02-07 | 2021-03-09 | 常州天地人和生物科技有限公司 | 一种高效、稳定的磁性免疫微球的制备和应用 |
| CN108329379B (zh) * | 2018-04-08 | 2022-01-28 | 诺华生物科技（武汉）有限责任公司 | H7亚型流感病毒h7n9的普通型/嵌合型病毒样颗粒及制备方法、应用和疫苗 |
| CN108840911B (zh) * | 2018-06-09 | 2021-03-30 | 西北农林科技大学 | 新城疫病毒基质蛋白的抗原表位、抗体、鉴定方法和应用 |
| WO2019246363A1 (en) | 2018-06-21 | 2019-12-26 | Icahn School Of Medicine At Mount Sinai | Mosaic influenza virus hemagglutinin polypeptides and uses thereof |
| SG11202100706UA (en) | 2018-07-23 | 2021-03-30 | Japan As Represented By Director General Of Nat Institute Of Infectious Diseases | Composition containing influenza vaccine |
| CN109097341B (zh) * | 2018-08-28 | 2021-09-24 | 青岛农业大学 | 一种同时表达ha和hef的复制缺陷型重组流感病毒 |
| CN111363017B (zh) * | 2018-12-25 | 2022-03-15 | 中国科学院微生物研究所 | A型流感病毒核蛋白s69位突变序列及其突变体与应用 |
| JP7545955B2 (ja) | 2019-03-04 | 2024-09-05 | 国立感染症研究所長 | インフルエンザｈａスプリットワクチンの製造方法 |
| TWI857017B (zh) * | 2019-03-04 | 2024-10-01 | 國立感染症研究所長代表之日本國 | 流感ha裂解疫苗之製造方法 |
| CN111134250A (zh) * | 2019-12-03 | 2020-05-12 | 海南大学 | 一种草地贪夜蛾幼虫食用人工饲料的配方和制作方法 |
| CN111298098B (zh) * | 2020-02-25 | 2021-10-29 | 中国科学院微生物研究所 | 卡泊芬净在制备抑制冠状病毒的产品中的应用 |
| WO2021188787A1 (en) * | 2020-03-19 | 2021-09-23 | Renibus Therapeutics, Inc. | Method for treatment of coronavirus infection |
| CN117229370B (zh) * | 2022-06-08 | 2024-11-01 | 中科南京生命健康高等研究院 | H5n6禽流感广谱性疫苗的开发及其应用 |
| WO2024097396A1 (en) * | 2022-11-05 | 2024-05-10 | Us Biologic, Inc. | Visco-elastic solid formulation for oral delivery of a biologically active agent |
| WO2025106608A2 (en) * | 2023-11-15 | 2025-05-22 | Red Queen Therapeutics, Inc. | Antiviral structurally stapled influenza peptides and uses thereof |
Family Cites Families (87)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ZA836080B (en) * | 1982-08-23 | 1984-04-25 | Scripps Clinic Res | Broad spectrum influenza antisera |
| US5182192A (en) | 1987-03-27 | 1993-01-26 | The Wistar Institute | Monoclonal antibodies against glycolipid antigens, methods of producing these antibodies, and use therefor |
| US6001634A (en) | 1989-08-28 | 1999-12-14 | Palese; Peter | Recombinant negative strand RNA viruses |
| US5854037A (en) | 1989-08-28 | 1998-12-29 | The Mount Sinai School Of Medicine Of The City University Of New York | Recombinant negative strand RNA virus expression systems and vaccines |
| US6887699B1 (en) | 1990-05-22 | 2005-05-03 | Medimmune Vaccines, Inc. | Recombinant negative strand RNA virus expression systems and vaccines |
| GB9015198D0 (en) | 1990-07-10 | 1990-08-29 | Brien Caroline J O | Binding substance |
| FR2664905B1 (fr) | 1990-07-18 | 1994-08-12 | Agronomique Inst Nat Rech | Baculovirus modifie, son procede d'obtention, et vecteurs d'expression obtenus a partir dudit baculovirus. |
| US5661016A (en) | 1990-08-29 | 1997-08-26 | Genpharm International Inc. | Transgenic non-human animals capable of producing heterologous antibodies of various isotypes |
| US5625126A (en) | 1990-08-29 | 1997-04-29 | Genpharm International, Inc. | Transgenic non-human animals for producing heterologous antibodies |
| US5633425A (en) | 1990-08-29 | 1997-05-27 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
| DE69127627T2 (de) | 1990-08-29 | 1998-02-19 | Genpharm Int | Produktion und Nützung nicht-menschliche transgentiere zur Produktion heterologe Antikörper |
| US5545806A (en) | 1990-08-29 | 1996-08-13 | Genpharm International, Inc. | Ransgenic non-human animals for producing heterologous antibodies |
| ATE408012T1 (de) | 1991-12-02 | 2008-09-15 | Medical Res Council | Herstellung von autoantikörpern auf phagenoberflächen ausgehend von antikörpersegmentbibliotheken |
| US5589174A (en) | 1992-09-17 | 1996-12-31 | Takara Shuzo Co., Ltd. | Anti-human influenza virus antibody |
| EP0621339B1 (en) | 1992-09-17 | 2001-10-24 | Takara Shuzo Co. Ltd. | Immunogenic human influenza A virus haemagglutinin polypeptides |
| JP3037554B2 (ja) | 1993-04-20 | 2000-04-24 | 寳酒造株式会社 | 免疫原性人工ポリペプチド |
| US6337070B1 (en) | 1993-04-29 | 2002-01-08 | Takara Shuzo Co., Ltd. | Polypeptides for use in generating anti-human influenza virus antibodies |
| GB9221654D0 (en) | 1992-10-15 | 1992-11-25 | Scotgen Ltd | Recombinant human anti-cytomegalovirus antibodies |
| WO1994016109A1 (en) * | 1993-01-15 | 1994-07-21 | Whitehead Institute For Biomedical Research | Membrane fusion events and means for altering same |
| WO1994017826A1 (en) | 1993-02-01 | 1994-08-18 | Smithkline Beecham Corporation | Vaccinal polypeptides |
| US5573916A (en) * | 1994-05-19 | 1996-11-12 | Coretech, Inc. | Immunogenic constructs comprising b-cell and t-cell epitopes on common carrier |
| US5622701A (en) | 1994-06-14 | 1997-04-22 | Protein Design Labs, Inc. | Cross-reacting monoclonal antibodies specific for E- and P-selectin |
| EP1978033A3 (en) | 1995-04-27 | 2008-12-24 | Amgen Fremont Inc. | Human antibodies derived from immunized xenomice |
| WO1996034096A1 (en) | 1995-04-28 | 1996-10-31 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
| US5916771A (en) | 1996-10-11 | 1999-06-29 | Abgenix, Inc. | Production of a multimeric protein by cell fusion method |
| ATE549918T1 (de) | 1996-12-03 | 2012-04-15 | Amgen Fremont Inc | Menschliche antikörper, die ausdrücklich menschliches tnf alpha binden |
| US6165476A (en) | 1997-07-10 | 2000-12-26 | Beth Israel Deaconess Medical Center | Fusion proteins with an immunoglobulin hinge region linker |
| ATE330015T1 (de) | 1999-04-29 | 2006-07-15 | Syngenta Ltd | Herbizidresistente pflanzen |
| CA2383105C (en) * | 1999-09-24 | 2010-01-26 | Smithkline Beecham Biologicals S.A. | Intranasal influenza virus vaccine |
| US7521220B2 (en) | 1999-11-26 | 2009-04-21 | Crucell Holland B.V. | Production of vaccines |
| DK1317559T3 (da) * | 2000-04-28 | 2009-03-23 | St Jude Childrens Res Hospital | DNA-transfektionssystem til frembringelse af smitsom negativstrenget RNA-virus |
| US6632620B1 (en) | 2000-06-22 | 2003-10-14 | Andrew N. Makarovskiy | Compositions for identification and isolation of stem cells |
| HUE027448T2 (en) | 2002-02-13 | 2016-09-28 | Wisconsin Alumni Res Found | Signal to pack flu virus vectors |
| US20040091503A1 (en) | 2002-08-20 | 2004-05-13 | Genitrix, Llc | Lectin compositions and methods for modulating an immune response to an antigen |
| CN1984999A (zh) | 2003-01-29 | 2007-06-20 | 纽约州立大学研究基金会 | 耐受诱导的靶向抗体产生 |
| WO2004075829A2 (en) * | 2003-01-30 | 2004-09-10 | Chiron Corporation | Adjuvanted influenza vaccine |
| JP4368594B2 (ja) | 2003-02-24 | 2009-11-18 | 株式会社インシリコサイエンス | タンパク質構造予測装置、タンパク質構造予測方法、プログラム、および、記録媒体 |
| KR20060035596A (ko) | 2003-05-05 | 2006-04-26 | 보이스 톰슨 인스터튜트 포 플랜트 리서치 | 외래유전자도입 식물로부터 유래된 면역보호성 조성물을제조하기 위한 벡터와 세포 |
| US8592197B2 (en) | 2003-07-11 | 2013-11-26 | Novavax, Inc. | Functional influenza virus-like particles (VLPs) |
| DK2261378T3 (da) * | 2003-11-04 | 2014-01-20 | Univ Tulane | Fremgangsmåde til hindring af virus:celle-fusion ved hæmning af funktionen af fusionsinitieringsregionen i RNA virus med klasse I membranfusogene kappeproteiner |
| ES2454266T3 (es) * | 2004-05-25 | 2014-04-10 | Medimmune, Llc | Variantes de la hemaglutinina y la neuraminidasa de influenza |
| WO2006104615A2 (en) * | 2005-02-24 | 2006-10-05 | University Of Massachusetts | Influenza nucleic acids, polypeptides, and uses thereof |
| US20070020238A1 (en) | 2005-06-01 | 2007-01-25 | David Baltimore | Method of targeted gene delivery using viral vectors |
| JP4758148B2 (ja) | 2005-06-14 | 2011-08-24 | 泰三 宇田 | インフルエンザウイルスのヘマグルチニンに対する抗体酵素 |
| PL1951299T3 (pl) * | 2005-11-04 | 2012-07-31 | Novartis Ag | Szczepionki przeciw grypie zawierające kombinacje adiuwantów cząsteczkowych i czynników wzmacniających immunogenność |
| HUE037464T2 (hu) | 2005-12-02 | 2018-08-28 | Icahn School Med Mount Sinai | Nem-natív felületi fehérjéket prezentáló kiméra Newcastle disease vírusok és alkalmazásuk |
| US7914797B2 (en) * | 2005-12-06 | 2011-03-29 | Yeda Research And Development Co. Ltd. At The Weizmann Institute Of Science | Influenza vaccine |
| US10183986B2 (en) * | 2005-12-15 | 2019-01-22 | Industrial Technology Research Institute | Trimeric collagen scaffold antibodies |
| WO2007103322A2 (en) | 2006-03-07 | 2007-09-13 | Vaxinnate Corporation | Compositions that include hemagglutinin, methods of making and methods of use thereof |
| CA2652452C (en) | 2006-05-15 | 2018-07-31 | Sea Lane Biotechnologies, Llc | Neutralizing antibodies to influenza viruses |
| US8148085B2 (en) | 2006-05-15 | 2012-04-03 | Sea Lane Biotechnologies, Llc | Donor specific antibody libraries |
| US9511134B2 (en) * | 2006-05-18 | 2016-12-06 | Epimmune Inc. | Inducing immune responses to influenza virus using polypeptide and nucleic acid compositions |
| EP2035565A4 (en) | 2006-06-30 | 2010-07-21 | Novavax Inc | METHODS OF ENHANCING THE INCORPORATION OF PROTEINS IN VIRUS-LIKE PARTICLES (VLPs) |
| BRPI0714495B8 (pt) | 2006-07-21 | 2021-05-25 | California Inst Of Techn | lentivírus deficiente para replicação recombinante pseudotipado |
| US8192927B2 (en) | 2006-09-07 | 2012-06-05 | Crucell Holland B.V. | Human bind molecules capable of neutralizing influenza virus h5n1 and uses thereof |
| ES2536401T3 (es) | 2006-09-11 | 2015-05-25 | Novartis Ag | Fabricación de vacunas contra virus de la gripe sin usar huevos |
| US8603467B2 (en) * | 2007-06-15 | 2013-12-10 | Xiamen University | Monoclonal antibodies binding to avian influenza virus subtype H5 haemagglutinin and uses thereof |
| EP2014279A1 (en) * | 2007-06-22 | 2009-01-14 | Pevion Biotech AG | Virosomes comprising hemagglutinin derived from an influenza virus produced in a cell line, compositions, methods of manufacturing, use thereof |
| CA2615372A1 (en) | 2007-07-13 | 2009-01-13 | Marc-Andre D'aoust | Influenza virus-like particles (vlps) comprising hemagglutinin |
| US20090092635A1 (en) | 2007-08-17 | 2009-04-09 | Wyeth | Heterologous prime-boost immunization regimen |
| EP2200639B1 (en) * | 2007-09-24 | 2016-03-30 | Government of the USA, as Represented by the Secretary, Department of Health and Human Services | Immunostimulatory combinations of tlr3 ligands with tlr2 and tlr9 agonists and methods of use |
| FR2921387B1 (fr) | 2007-09-26 | 2012-04-20 | Sanofi Pasteur | Procede de production du virus de la grippe |
| GB0810305D0 (en) | 2008-06-05 | 2008-07-09 | Novartis Ag | Influenza vaccination |
| NZ587108A (en) | 2007-11-27 | 2013-04-26 | Medicago Inc | Recombinant influenza virus-like particles (vlps) produced in transgenic plants expressing hemagglutinin |
| CN101970483A (zh) | 2007-12-06 | 2011-02-09 | 达纳-法伯癌症研究公司 | 抗流感病毒抗体及其使用方法 |
| ITTO20080204A1 (it) | 2008-03-17 | 2009-09-18 | Pomona Biotechnologies Llc | Anticorpi monoclonali atti a reagire con una pluralita di sottotipi del virus influenzale a |
| CN102046656A (zh) | 2008-03-28 | 2011-05-04 | 航道生物技术有限责任公司 | 针对病毒抗原的中和性分子 |
| GB0905570D0 (en) | 2009-03-31 | 2009-05-13 | Novartis Ag | Combined vaccines |
| ES2524553T3 (es) * | 2008-06-17 | 2014-12-10 | Apogenix Gmbh | Receptores multiméricos de TNF |
| EP2300609B1 (en) | 2008-06-25 | 2013-11-20 | INSERM - Institut National de la Santé et de la Recherche Médicale | Novel immunoadjuvant flagellin-based compounds and use thereof |
| WO2010003235A1 (en) | 2008-07-08 | 2010-01-14 | Medicago Inc. | Soluble recombinant influenza antigens |
| WO2010117786A1 (en) | 2009-03-30 | 2010-10-14 | Mount Sinai School Of Medicine Of New York University | Influenza virus vaccines and uses thereof |
| MY183517A (en) | 2009-05-11 | 2021-02-24 | Janssen Vaccines & Prevention Bv | Human binding molecules capable of neutralizing influenza virus h3n2 and uses thereof |
| JP5941841B2 (ja) | 2009-05-26 | 2016-06-29 | アイカーン スクール オブ メディシン アット マウント サイナイ | 周期的投与によって作製されたインフルエンザウイルスに対するモノクローナル抗体及びその使用 |
| EP3228627A1 (en) | 2009-06-24 | 2017-10-11 | Medicago Inc. | Chimeric influenza virus- like particles comprising hemagglutinin |
| US8828406B2 (en) * | 2009-07-30 | 2014-09-09 | Icahn School Of Medicine At Mount Sinai | Influenza viruses and uses thereof |
| JP5463107B2 (ja) | 2009-09-14 | 2014-04-09 | 独立行政法人国立国際医療研究センター | 新型インフルエンザを特異的に鑑別するモノクローナル抗体とそれを利用した免疫検出試薬 |
| JP2013060367A (ja) | 2010-01-15 | 2013-04-04 | Osaka Univ | 抗インフルエンザ抗体及びインフルエンザ検出用デバイス |
| US8298820B2 (en) * | 2010-01-26 | 2012-10-30 | The Trustees Of The University Of Pennsylvania | Influenza nucleic acid molecules and vaccines made therefrom |
| AU2011217903B2 (en) | 2010-02-18 | 2017-03-02 | Mount Sinai School Of Medicine | Vaccines for use in the prophylaxis and treatment of influenza virus disease |
| EA021977B1 (ru) | 2010-03-08 | 2015-10-30 | Селлтрион, Инк. | Моноклональные антитела человека, полученные из в-клеток человека и обладающие нейтрализующей активностью против вирусов гриппа а |
| US9708373B2 (en) | 2010-03-30 | 2017-07-18 | Icahn School Of Medicine At Mount Sinai | Influenza virus vaccine and uses thereof |
| WO2012009790A1 (en) | 2010-07-22 | 2012-01-26 | Schrader John W | Cross-protective pathogen protection, methods and compositions thereof |
| WO2013043729A1 (en) | 2011-09-20 | 2013-03-28 | Mount Sinai School Of Medicine | Influenza virus vaccines and uses thereof |
| EP3566714A1 (en) | 2011-11-28 | 2019-11-13 | Janssen Vaccines & Prevention B.V. | Influenza virus vaccines and uses thereof |
| WO2014090865A1 (en) | 2012-12-11 | 2014-06-19 | Vib Vzw | Anti-influenza antibody |
| EP2934581B1 (en) | 2012-12-18 | 2022-09-14 | Icahn School of Medicine at Mount Sinai | Influenza virus vaccines and uses thereof |
-
2011
- 2011-02-18 AU AU2011217903A patent/AU2011217903B2/en not_active Ceased
- 2011-02-18 BR BR112012020839A patent/BR112012020839A2/pt not_active Application Discontinuation
- 2011-02-18 JP JP2012554060A patent/JP2013520172A/ja not_active Withdrawn
- 2011-02-18 KR KR1020127024205A patent/KR20120132506A/ko not_active Ceased
- 2011-02-18 MX MX2012009581A patent/MX342716B/es active IP Right Grant
- 2011-02-18 US US13/579,845 patent/US9701723B2/en active Active
- 2011-02-18 WO PCT/US2011/025467 patent/WO2011103453A2/en not_active Ceased
- 2011-02-18 CA CA2790380A patent/CA2790380A1/en not_active Abandoned
- 2011-02-18 EP EP11745345.6A patent/EP2536425B1/en active Active
- 2011-02-18 CN CN201180019658.1A patent/CN102939096B/zh not_active Expired - Fee Related
-
2016
- 2016-05-24 JP JP2016103689A patent/JP2016196472A/ja not_active Withdrawn
-
2018
- 2018-07-03 JP JP2018126633A patent/JP2018166515A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| US20130209499A1 (en) | 2013-08-15 |
| BR112012020839A2 (pt) | 2017-11-21 |
| JP2016196472A (ja) | 2016-11-24 |
| KR20120132506A (ko) | 2012-12-05 |
| JP2013520172A (ja) | 2013-06-06 |
| AU2011217903B2 (en) | 2017-03-02 |
| MX342716B (es) | 2016-10-11 |
| US9701723B2 (en) | 2017-07-11 |
| JP2018166515A (ja) | 2018-11-01 |
| MX2012009581A (es) | 2013-01-29 |
| EP2536425A4 (en) | 2014-11-05 |
| CN102939096A (zh) | 2013-02-20 |
| US20170114103A9 (en) | 2017-04-27 |
| WO2011103453A3 (en) | 2011-12-29 |
| CN102939096B (zh) | 2016-03-02 |
| AU2011217903A1 (en) | 2012-09-13 |
| EP2536425B1 (en) | 2019-06-19 |
| WO2011103453A2 (en) | 2011-08-25 |
| EP2536425A2 (en) | 2012-12-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA2790380A1 (en) | Vaccines for use in the prophylaxis and treatment of influenza virus disease | |
| US9943589B2 (en) | Immunopotentiator-linked oligomeric influenza immunogenic compositions | |
| US9889194B2 (en) | Immunogenic composition for MERS coronavirus infection | |
| JP2016196472A5 (enExample) | ||
| RU2015142996A (ru) | Пептидная вакцина для предупреждения и иммунотерапии деменции альцгеймеровского типа | |
| Yang et al. | A triple-RBD-based mucosal vaccine provides broad protection against SARS-CoV-2 variants of concern | |
| JP2013520172A5 (enExample) | ||
| EP2640419B1 (en) | Respiratory syncytial virus vaccine | |
| JP2013526849A5 (enExample) | ||
| JP2012501959A5 (enExample) | ||
| WO2007066334A9 (en) | Improved influenza vaccine | |
| JP2017522319A5 (enExample) | ||
| RU2015141214A (ru) | Вакцины против Chlamydia sp. | |
| TW202308685A (zh) | 冠狀病毒和流感病毒組合物及其使用方法 | |
| JP2009520758A5 (enExample) | ||
| JP2015529677A5 (enExample) | ||
| JP2021524280A (ja) | ハウスダストダニアレルギーの処置および予防 | |
| EP2739307B1 (en) | Vlps containing ligands and methods related thereto | |
| WO2011017442A3 (en) | Anti-rsv immunogens and methods of immunization | |
| JP2020536925A5 (enExample) | ||
| RU2007129962A (ru) | Универсальная вакцина против вируса гриппа птиц | |
| JP2012501351A5 (enExample) | ||
| WO2004062584A3 (en) | Therapeutic and prophylactic vaccine for the treatment and prevention of papillomavirus infection | |
| Chowdhury et al. | Heterosubtypic protective immunity against widely divergent influenza subtypes induced by fusion protein 4sM2 in BALB/c mice | |
| Tang et al. | Codelivery of SARS-CoV-2 Prefusion-Spike Protein with CBLB502 by a Dual-Chambered Ferritin Nanocarrier Potentiates Systemic and Mucosal Immunity |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request |
Effective date: 20160212 |
|
| FZDE | Discontinued |
Effective date: 20200831 |
|
| FZDE | Discontinued |
Effective date: 20200831 |